U.S. Life Science 2008 Top 10 Predictions

Table of Contents

• Table of Contents
• Predictions
• In This Report
• Situation Overview
• Table: Select Blockbuster Drug Patent Protection Expiration Date and 2006 U.S. Revenue
• Future Outlook
  • Prediction #1: The Use of Business Intelligence/Analytics Tools to More Efficiently Manage the Life Science Industry Will Increase Rapidly
    • BI Will Begin to Permeate Pharma Discovery to Enable Management to Quantify Incremental Progress and Increase Information Transparency Across the Organization
    • Clinical Development Will Finally Realize the Value of BI Tools
    • Pharmaceutical Sales Look for a Boost from BI Tools
  • Prediction #2: Outsourcing Becomes Instrumental to Long-Term Company Success as Industry Focus on Cost Reduction Continues to Increase
    • 2008 Will See Significant Investment and Growth in Global R&D by Major Pharma Seeking Low-Cost and Emerging Market Solutions
    • Clinical Development Will Continue to Struggle with Outsourcing Strategies
    • IT Outsourcing in Pharma Manufacturing Continues Its Climb
  • Prediction #3: Drug Safety Will Remain Front and Center as a Primary Concern in 2008
    • Clinical Safety Management Will Dominate the Discussion in 2008
    • Public Perception of Drug Safety Will Continue to Slow the Development and Approval of New Drugs
  • Prediction #4: Revenue Leakage Will Find Its Way onto the Radar Screen at Most Pharmaceutical Companies and Will Become a Strategic Component of Cost-Cutting Strategies
  • Prediction #5: Spending on Commercial Software and Integration Services Will Overtake Homegrown and Custom Software Development Efforts
  • Prediction #6: Investment in SFA Applications Will Increase as Companies Upgrade, Enhance, and Rip and Replace Outdated IT Solutions with Next-Generation Applications to Improve Sales Force Efficiency and Effectiveness
  • Prediction #7: Progress in Genetic Discovery Will Accelerate the Development of Profiling Diagnostics and Targeted Therapeutics
  • Prediction #8: Knowledge-Based Processes Will Continue to Grow, Based on the Need to More Effectively Use Rapidly Growing Available Data
  • Prediction #9: Clinical Data Becomes Increasingly Commoditized in 2008
  • Prediction #10: Operational Issues Surrounding the Use of Biomarkers Will Limit Utility
• Essential Guidance
• Learn More
  • Related Research
  • Synopsis